<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113199</article-id><article-id pub-id-type="publisher-id">ACM-41382</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_44044394.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  EV71疫苗预防重症手足口病的临床观察
  Clinical Observation of EV71 Vaccine in Prevention of Severe Case in Children with Hand Foot and Mouth Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尹</surname><given-names>秀志</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>继安</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>聂</surname><given-names>秀真</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>丽艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>世花</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>双双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>道彦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>爱伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东大学齐鲁儿童医院感染性疾病科，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1393</fpage><lpage>1398</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本研究主要是研究分析在手足口病患儿中EV71疫苗接种后对重症手足口病的影响。方法：收集2018年收治的手足口病患儿1434人，其中接种EV71疫苗169人，根据患儿有无并发脑炎分为轻型组及重症组。对患儿进行血EV71IgM、CoxA16IgM检测，咽拭子PCR检测肠道病毒核酸。结果：2018年我们收治的手足口病病人与2016年、2017年相比有所减少，疱疹性咽峡炎发病率有所升高，脑炎发病率下降。在2018年收治的1434病人中接种疫苗169人，占11.8%，未接种疫苗者1265人，占88.2%，脑炎患者221人，占15.4%。在接种疫苗与未接种疫苗患儿中性别、手足口病与疱疹性咽峡炎发病率无明显差异，但接种疫苗患儿的脑炎发病率低于未接种疫苗患儿(P = 0.039)。疫苗接种率在轻型组与重症组之间无差异，而EV71IgM与CoxA16PCR阳性率有明显的差异，脑炎发病中EV71感染为主。在169例接种患儿中，男性占62.1%，发病以手足口病为主，但接种疫苗后仍有10.7%的患儿并发脑炎。结论：本研究显示在我们收治的手足口病患儿中，疫苗接种后疱疹性咽峡炎发病率有所上升，脑炎的发生率下降，提示EV71疫苗接种对手足口病重症的发生有保护作用，但有些患儿接种后未产生保护作用或者保护作用较弱，尚需进一步观察研究。
    Objective: The purpose of this study was to investigate the effect of EV71 vaccination on severe case in children with HFMD. Methods: We collected a total of 1434 patients with HFMD admitted for treatment in 2018, among them 169 were vaccinated with EV71 vaccine. They were divided into the mild group and the severe group according to the presence or absence of complicated encephalitis. Blood EV71IgM and CoxA16IgM were detected, and enterovirus nucleic acid was detected by PCR with pharyngeal swab. Results: In 2018, the number of patients with HFMD admitted for treatment decreased compared with that of 2016 and 2017, and the incidence of herpangina increased and the incidence of encephalitis decreased. Among the 1434 patients admitted in 2018, 169 (11.8%) were vaccinated, 1265 (88.2%) were unvaccinated, and 221 (15.4%) were diagnosed with encephalitis. There were no significant differences in gender, incidence rate of HFMD and herpangina between vaccinated and unvaccinated children, but the incidence rate of encephalitis in vaccinated patients was lower than that in unvaccinated patients (P = 0.039). There was no difference in vaccination rates between the mild group and the severe group, while the positive rate of EV71IgM and CoxA16PCR was significantly different, and EV71 infection was the main infection in the incidence of encephalitis. Among the 169 patients vaccinated, 62.1% were males, the incidence HFMD was the main disease, but 10.7% of the vaccinated patients still developed encephalitis. Conclusion: This study showed that herpangina incidence has increased after vaccination in patients in our department, and the incidence of encephalitis has decreased. It shows that EV71 vaccine in the occurrence of severe HFMD has a protective effect, but some patients vaccinated did not produce protection or protection was weak, which still needs further study. 
  
 
</p></abstract><kwd-group><kwd>EV71疫苗，手足口病，重症，保护作用, EV71 Vaccine</kwd><kwd> Hand Foot and Mouth Disease</kwd><kwd> Severe Case</kwd><kwd> Protective Effect</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究主要是研究分析在手足口病患儿中EV71疫苗接种后对重症手足口病的影响。方法：收集2018年收治的手足口病患儿1434人，其中接种EV71疫苗169人，根据患儿有无并发脑炎分为轻型组及重症组。对患儿进行血EV71IgM、CoxA16IgM检测，咽拭子PCR检测肠道病毒核酸。结果：2018年我们收治的手足口病病人与2016年、2017年相比有所减少，疱疹性咽峡炎发病率有所升高，脑炎发病率下降。在2018年收治的1434病人中接种疫苗169人，占11.8%，未接种疫苗者1265人，占88.2%，脑炎患者221人，占15.4%。在接种疫苗与未接种疫苗患儿中性别、手足口病与疱疹性咽峡炎发病率无明显差异，但接种疫苗患儿的脑炎发病率低于未接种疫苗患儿(P = 0.039)。疫苗接种率在轻型组与重症组之间无差异，而EV71IgM与CoxA16PCR阳性率有明显的差异，脑炎发病中EV71感染为主。在169例接种患儿中，男性占62.1%，发病以手足口病为主，但接种疫苗后仍有10.7%的患儿并发脑炎。结论：本研究显示在我们收治的手足口病患儿中，疫苗接种后疱疹性咽峡炎发病率有所上升，脑炎的发生率下降，提示EV71疫苗接种对手足口病重症的发生有保护作用，但有些患儿接种后未产生保护作用或者保护作用较弱，尚需进一步观察研究。</p></sec><sec id="s2"><title>关键词</title><p>EV71疫苗，手足口病，重症，保护作用</p></sec><sec id="s3"><title>Clinical Observation of EV71 Vaccine in Prevention of Severe Case in Children with Hand Foot and Mouth Disease<sup> </sup></title><p>Xiuzhi Yin, Ji’an Li<sup>*</sup>, Xiuzhen Nie, Liyan Liu, Shihua Liu, Na Li, Ping Wang, Shuangshuang Song, Daoyan Xu, Aiwei Lin</p><p>Infectious Diseases Department, Qilu Children’s Hospital of Shandong University, Jinan Shandong</p><p><img src="//html.hanspub.org/file/82-1571879x5_hanspub.png" /></p><p>Received: Feb. 25<sup>th</sup>, 2021; accepted: Mar. 12<sup>th</sup>, 2021; published: Mar. 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/82-1571879x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The purpose of this study was to investigate the effect of EV71 vaccination on severe case in children with HFMD. Methods: We collected a total of 1434 patients with HFMD admitted for treatment in 2018, among them 169 were vaccinated with EV71 vaccine. They were divided into the mild group and the severe group according to the presence or absence of complicated encephalitis. Blood EV71IgM and CoxA16IgM were detected, and enterovirus nucleic acid was detected by PCR with pharyngeal swab. Results: In 2018, the number of patients with HFMD admitted for treatment decreased compared with that of 2016 and 2017, and the incidence of herpangina increased and the incidence of encephalitis decreased. Among the 1434 patients admitted in 2018, 169 (11.8%) were vaccinated, 1265 (88.2%) were unvaccinated, and 221 (15.4%) were diagnosed with encephalitis. There were no significant differences in gender, incidence rate of HFMD and herpangina between vaccinated and unvaccinated children, but the incidence rate of encephalitis in vaccinated patients was lower than that in unvaccinated patients (P = 0.039). There was no difference in vaccination rates between the mild group and the severe group, while the positive rate of EV71IgM and CoxA16PCR was significantly different, and EV71 infection was the main infection in the incidence of encephalitis. Among the 169 patients vaccinated, 62.1% were males, the incidence HFMD was the main disease, but 10.7% of the vaccinated patients still developed encephalitis. Conclusion: This study showed that herpangina incidence has increased after vaccination in patients in our department, and the incidence of encephalitis has decreased. It shows that EV71 vaccine in the occurrence of severe HFMD has a protective effect, but some patients vaccinated did not produce protection or protection was weak, which still needs further study.</p><p>Keywords:EV71 Vaccine, Hand Foot and Mouth Disease, Severe Case, Protective Effect</p><disp-formula id="hanspub.41382-formula129"><graphic xlink:href="//html.hanspub.org/file/82-1571879x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/82-1571879x8_hanspub.png" /> <img src="//html.hanspub.org/file/82-1571879x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>手足口病(Hand foot and mouth disease, HFMD)是由肠道病毒引起的一种急性传染病，其中以柯萨奇A组16型(coxsackievirus A16, CoxA16)和肠道病毒71型(enterovirus 71, EV71)感染最为常见，主要侵犯5岁以下儿童 [<xref ref-type="bibr" rid="hanspub.41382-ref1">1</xref>]，其中EV71是引起手足口病重症最常见的病原体 [<xref ref-type="bibr" rid="hanspub.41382-ref2">2</xref>]。近年在亚太地区呈现流行强度高、重症和死亡人数多的特点，已成为该地区的重大公共卫生问题 [<xref ref-type="bibr" rid="hanspub.41382-ref3">3</xref>]。对于手足口病的预防已迫在眉睫，我国自2008年开始自主研发疫苗，2015年12月30日，EV71疫苗获得国家食品药品监督管理总局批准，取得新药证书和药品生产批件。该疫苗在2011年完成I期、II期临床试验，显示该疫苗具有良好的安全性和免疫原性。在此基础上，2012年开展了III期临床试验(北京微谷生物医药有限公司(Vigoo)、中国科兴生物制品有限公司(Inovac)和中国医学科学院(CAMS)所研制的疫苗在2013年已完成了临床III期试验)，并随后完成了长达一年的流行病学保护效果观察，显示该疫苗表现出良好的免疫原性与安全性，对于EV71病毒引起的手足口病或疱疹性咽峡炎保护率达到94.8%，能够在婴幼儿目标人群中预防EV71相关的手足口病。此外，研究还显示该疫苗对手足口病伴随的神经系统并发症(导致死亡的主要原因)有效率均为100% [<xref ref-type="bibr" rid="hanspub.41382-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41382-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41382-ref6">6</xref>]。在诊断、治疗方法有限的情况下，使用EV71疫苗预防手足口病，尤其是预防由EV71病毒造成的重症及死亡病例成了战胜疾病的关键。不过有疾控专家指出：手足口病疫苗并非“一针就灵”，引起手足口病的肠道病毒有20多种，当前的手足口病EV71疫苗只能预防由EV71感染所致的手足口病等，不能预防其他肠道病毒感染所致的手足口病。从2016年3月22日全球首针EV71疫苗在北京朝阳区接种，7月29日起，手足口病疫苗开始进驻北京市各预防免疫门诊，适龄儿童可以选择接种。2016年4月1日开始也在山东地区开始接种(主要是科兴、中科院研发的EV71灭活疫苗)。关于接种后手足口病发病及脑炎发病情况的报道相对较少，我们收集接种2018年1434手足口病病人，其中接种EV71疫苗169人，并发脑炎患儿221人，用以观察研究EV71疫苗的临床保护性作用。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 对象</title><p>收集我院2018年收治的手足口病患儿1434人，收治病人临床表现和/或病原的诊断标准符合“手足口病诊疗指南(2018版)” [<xref ref-type="bibr" rid="hanspub.41382-ref7">7</xref>]。其中接种EV71疫苗169人。根据患儿有无并发脑炎分为轻型组及脑炎组。本研究案例由山东大学齐鲁儿童医院伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>对患儿进行肠道病毒EV71抗体(enterovirus 71 antibody M, EV71IgM)，柯萨奇病毒A16抗体M (coxsackie virus A16 antibody M, CoxA16IgM)，采集咽拭子标本采用实时定量PCR检测核酸，进行肠道病毒(enterovirus, EV)检测。回顾性分析疫苗接种对手足口病、疱疹性咽峡炎发展为重症的影响，并进行轻、重症比较分析。</p></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>用SPSS16.0软件分析，非正态分布资料用中位数表示，采用秩和检验分析；计数资料用率(%)表示，应用χ<sup>2</sup>检验或Fisher’s Exact Test进行分析，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基本情况</title><p>2018年我们收治1434病人中男性886人(61.8%)，女性548 (38.2%)；手足口病878例，占61.2%，疱疹性咽峡炎556例，占38.8%；EV71疫苗接种169人，占11.8%；未接种1265人，占88.2%。并发脑炎221例，占15.4%，其中重症脑炎2例，占0.14%。见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic situatio</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >比率(%)</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >1.9 (1.3~3.3)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >886</td><td align="center" valign="middle" >61.8</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >548</td><td align="center" valign="middle" >38.2</td></tr><tr><td align="center" valign="middle" >手足口病</td><td align="center" valign="middle" >878</td><td align="center" valign="middle" >61.2</td></tr><tr><td align="center" valign="middle" >疱疹性咽峡炎</td><td align="center" valign="middle" >556</td><td align="center" valign="middle" >38.8</td></tr><tr><td align="center" valign="middle" >接种EV71疫苗</td><td align="center" valign="middle" >169</td><td align="center" valign="middle" >11.8</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >未接种EV71疫苗</th><th align="center" valign="middle" >1265</th><th align="center" valign="middle" >88.2</th></tr></thead><tr><td align="center" valign="middle" >并发脑炎</td><td align="center" valign="middle" >221</td><td align="center" valign="middle" >15.4</td></tr><tr><td align="center" valign="middle" >重症脑炎</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.14</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 基本情况</p></sec><sec id="s7_2"><title>3.2. 发病情况</title><p>与2016年、2017年相比，2018年手足口病及并发脑炎患儿占收治病人的比率下降，疱疹性咽峡炎患儿占收治病人的比率升高。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Hand foot and mouth disease and associated encephalitis in recent 3 year</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目/年份</th><th align="center" valign="middle" >2016年(1573例)</th><th align="center" valign="middle" >2017年(1583例)</th><th align="center" valign="middle" >2018年(1434例)</th></tr></thead><tr><td align="center" valign="middle" >手足口病(%)</td><td align="center" valign="middle" >1114 (70.8)</td><td align="center" valign="middle" >1098 (69.4)</td><td align="center" valign="middle" >878 (61.2)</td></tr><tr><td align="center" valign="middle" >疱疹性咽峡炎(%)</td><td align="center" valign="middle" >459 (29.2)</td><td align="center" valign="middle" >485 (30.6)</td><td align="center" valign="middle" >556 (38.8)</td></tr><tr><td align="center" valign="middle" >脑炎(%)</td><td align="center" valign="middle" >318 (20.2)</td><td align="center" valign="middle" >477 (30.1)</td><td align="center" valign="middle" >221 (15.4)</td></tr></tbody></table></table-wrap><p>表2. 近三年手足口病及并发脑炎</p><p>2018年收治病人中有169例接种疫苗，未接种疫苗1265例，在接种疫苗与未接种疫苗患儿中男女无明显差异，但男性接种105例，占62.1%；手足口病与疱疹性咽峡炎发病率无明显差异；接种疫苗患儿的脑炎发病率低于未接种疫苗患儿(P = 0.039)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The incidence of vaccinations and non-vaccinations case</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >接种疫苗169 (例)</th><th align="center" valign="middle" >未接种疫苗1265 (例)</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >男(%)</td><td align="center" valign="middle" >105 (62.1)</td><td align="center" valign="middle" >781 (61.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女(%)</td><td align="center" valign="middle" >64 (37.9)</td><td align="center" valign="middle" >484 (38.3)</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >0.922</td></tr><tr><td align="center" valign="middle" >手足口病(%)</td><td align="center" valign="middle" >106 (62.7)</td><td align="center" valign="middle" >772 (61.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >疱疹性咽峡炎(%)</td><td align="center" valign="middle" >63 (37.3)</td><td align="center" valign="middle" >493 (39.0)</td><td align="center" valign="middle" >0.180</td><td align="center" valign="middle" >0.671</td></tr><tr><td align="center" valign="middle" >脑炎(%)</td><td align="center" valign="middle" >18 (10.7)</td><td align="center" valign="middle" >203 (16.1)</td><td align="center" valign="middle" >3.623</td><td align="center" valign="middle" >0.039</td></tr></tbody></table></table-wrap><p>表3. 接种疫苗与未接种疫苗发病情况</p></sec><sec id="s7_3"><title>3.3. 轻重型比较</title><p>轻型组与脑炎组间比较：年龄、性别、疫苗接种率在轻型组与脑炎组之间无差异；EV71IgM与CoxA16PCR阳性率有明显的差异，而CoxA16IgM、EVPCR、EV71PCR比较无明显差异，在脑炎的发病中主要是EV71感染引起。见表4。</p><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of mild and severe case</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >轻型组(1213例)</th><th align="center" valign="middle" >重型组(221例)</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >1.90 (1.30~3.30)</td><td align="center" valign="middle" >1.90 (1.40~3.35)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.295</td></tr><tr><td align="center" valign="middle" >男(%)</td><td align="center" valign="middle" >743 (61.3)</td><td align="center" valign="middle" >143 (64.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女(%)</td><td align="center" valign="middle" >470 (38.7)</td><td align="center" valign="middle" >78 (35.3)</td><td align="center" valign="middle" >0.944</td><td align="center" valign="middle" >0.331</td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle" >EV71疫苗接种(%)</th><th align="center" valign="middle" >151 (12.4)</th><th align="center" valign="middle" >18 (8.1)</th><th align="center" valign="middle" >3.330</th><th align="center" valign="middle" >0.070</th></tr></thead><tr><td align="center" valign="middle" >EV71疫苗未接种(%)</td><td align="center" valign="middle" >1062 (87.6)</td><td align="center" valign="middle" >203 (91.9)</td><td align="center" valign="middle" >3.328</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >EV71IgM阳性(%)</td><td align="center" valign="middle" >317 (26.1)</td><td align="center" valign="middle" >90 (40.7)</td><td align="center" valign="middle" >19.578</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >CoxA16IgM阳性(%)</td><td align="center" valign="middle" >136 (11.2)</td><td align="center" valign="middle" >32 (14.5)</td><td align="center" valign="middle" >1.930</td><td align="center" valign="middle" >0.165</td></tr><tr><td align="center" valign="middle" >EVPCR阳性(%)</td><td align="center" valign="middle" >439 (36.2)</td><td align="center" valign="middle" >70 (31.7)</td><td align="center" valign="middle" >1.666</td><td align="center" valign="middle" >0.197</td></tr><tr><td align="center" valign="middle" >EV71PCR阳性(%)</td><td align="center" valign="middle" >264 (21.8)</td><td align="center" valign="middle" >43 (19.5)</td><td align="center" valign="middle" >0.591</td><td align="center" valign="middle" >0.442</td></tr><tr><td align="center" valign="middle" >CoxA16PCR阳性(%)</td><td align="center" valign="middle" >57 (4.7)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >10.815</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap></table-wrap-group><p>表4. 轻重型病例比较</p><p>注：EV71IgM，肠道病毒71型IgM；CoxA16IgM，柯萨奇病毒A16型IgM；EVPCR，肠道病毒通用型PCR；EV71PCR，肠道病毒71型PCR；CoxA16PCR，柯萨奇病毒A16型PCR。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>EV71疫苗在全国预防接种3年多的时间(微谷、科兴、中科院三家研发的肠道病毒71型灭活疫苗)，尽管III期临床试验显示对于EV71引起的手足口病或疱疹性咽峡炎保护率达到94.8%，且该疫苗对手足口病伴随的神经系统并发症有效率均为100%，但上市后IV期临床试验的观察数据，疫苗的效果和安全性的评价相对较少。余宏杰课题组研究发现EV-A71疫苗可有效预防6~71月龄儿童感染EV-A71引起的非重症HFMD，且接种两剂次EV-A71疫苗预防非重症结局的效果优于重症结局，全程接种针对非重症病例的疫苗效果为91.1%，针对重症病例为73.3% [<xref ref-type="bibr" rid="hanspub.41382-ref8">8</xref>]。2016年EV71疫苗启动接种以来，由于宣传、认识、接种缴费等因素山东地区2016年及2017年疫苗接种率较低，随着认识的提高，2018年接种率有所提高。与2016年、2017年相比，我院2018年手足口病及重型并发脑炎患儿占收治病人的比率下降，疱疹性咽峡炎患儿占收治病人的比率升高。在2018年收治的1434例患儿中接种疫苗169例，占11.8%，未接种疫苗1265例，占88.2%，脑炎患者221例，占15.4%。接种疫苗患儿的脑炎发病率低于未接种疫苗患儿(P = 0.039)，说明接种疫苗对并发脑炎有保护作用，此与徐宏杰课题组研究结果相似。疫苗接种率在轻型组与脑炎组之间无差异，而EV71IgM与CoxA16PCR阳性率有明显的差异，提示在脑炎发病中主要是EV71感染引起。在169例接种患儿中，男孩接种比例较高，发病以手足口病为主，但接种疫苗后仍有10.7%的患儿并发脑炎，说明有些患儿接种后未产生保护作用或者是保护作用较弱。</p><p>相关文献表明，引发手足口病的肠道病毒之间感染后不能形成有效的交叉保护，同一类型肠道病毒感染引起手足口病后是否能获得持久性特异性免疫力需进一步研究 [<xref ref-type="bibr" rid="hanspub.41382-ref9">9</xref>]。因此，有手足口病既往史的儿童仍然存在再度患手足口病的可能，对这部分儿童依旧有接种疫苗的必要性。</p><p>本研究显示疫苗接种后在我们收治的患儿中手足口病发病率下降，疱疹性咽峡炎发病率有所上升，脑炎发生率下降，提示EV71疫苗接种对手足口病重症的发生有保护作用，但是有些患儿接种后未产生保护作用或者保护作用较弱，其原因尚需进一步观察研究。但由于是我们单个中心收集的病例数及时限限制，本研究存在一定的局限性，我们将继续收集病例进行跟踪分析研究。</p></sec><sec id="s9"><title>基金项目</title><p>济南市卫生健康委员会科技发展计划项目(2017-1-42)。</p></sec><sec id="s10"><title>文章引用</title><p>尹秀志,李继安,聂秀真,刘丽艳,刘世花,李 娜,王 平,宋双双,徐道彦,林爱伟. EV71疫苗预防重症手足口病的临床观察Clinical Observation of EV71 Vaccine in Prevention of Severe Case in Children with Hand Foot and Mouth Disease[J]. 临床医学进展, 2021, 11(03): 1393-1398. https://doi.org/10.12677/ACM.2021.113199</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41382-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">卫生部. 手足口病预防控制指南[R]. 北京: 卫生部, 2009.</mixed-citation></ref><ref id="hanspub.41382-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">许园园, 覃肇源, 蒋小云. 儿童重症手足口病的研究进展[J]. 国际儿科学杂志, 2015, 42(2): 128-131.</mixed-citation></ref><ref id="hanspub.41382-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.C., Tang, S.Q., Li, Y.M., et al. (2010) A Comparison of the Biological Characteristics of EV71 C4 Subtypes from Different Epidemic Strains. Virologica Sinica, 25, 8-106. &lt;br&gt;https://doi.org/10.1007/s12250-010-3102-8</mixed-citation></ref><ref id="hanspub.41382-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Li, R., Liu, L., Mo, Z., et al. (2014) An Inactivated Enterovirus 71 Vaccine in Healthy Children. New England Journal of Medicine, 370, 829-837. &lt;br&gt;https://doi.org/10.1056/NEJMoa1303224</mixed-citation></ref><ref id="hanspub.41382-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, F.C., Xu, W.B., Xia, J.L., et al. (2014) Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China. New England Journal of Medicine, 370, 818-828. &lt;br&gt;https://doi.org/10.1056/NEJMoa1304923</mixed-citation></ref><ref id="hanspub.41382-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, F.C., Meng, F.Y., Li, J.X., et al. (2013) Efficacy, Safety, and Immunology of an Inactivated Alum-Adjuvant Enterovirus 71 Vaccine in Children in China: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet, 381, 2024-2032. &lt;br&gt;https://doi.org/10.1016/S0140-6736(13)61049-1</mixed-citation></ref><ref id="hanspub.41382-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生健康委员. 手足口病诊疗指南(2018年版) [M].  
http://www.nhc.gov.cn/yzygj/s3594q/201805/5db274d8697a41ea84e88eedd8bf8f63.shtml, 2015-05-15.</mixed-citation></ref><ref id="hanspub.41382-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Zhou, Y., Cheng, Y., et al. (2019) Effectiveness of EV-A71 Vaccination in Prevention of Paediatric Hand, Foot, and Mouth Disease Associated with EV-A71 Virus Infection Requiring Hospitalisation in Henan, China, 2017-18: A Test-Negative Case-Control Study. Lancet Child &amp; Adolescent Health, 3, 697-704.  
&lt;br&gt;https://doi.org/10.1016/S2352-4642(19)30185-3</mixed-citation></ref><ref id="hanspub.41382-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">陈纯, 肖新才, 丁鹏, 等. 2008-2011年广州市手足口病重复感染情况分析[J]. 中国热带医学, 2012, 12(8): 934-936.</mixed-citation></ref></ref-list></back></article>